116
Participants
Start Date
March 16, 2021
Primary Completion Date
July 29, 2025
Study Completion Date
July 29, 2025
Pembrolizumab/Quavonlimab
Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
Lenvatinib
Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
Pembrolizumab
Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
NATIONAL CHENG-KUNG UNI. HOSP.-Clinical Trial Research Team of Liver Diseases ( Site 0354), Tainan City
CHUV (centre hospitalier universitaire vaudois) ( Site 0333), Lausanne
Hôpitaux Universitaires de Genève (HUG) ( Site 0335), Geneva
Inselspital Bern-Universitätsklinik für Viszerale Chirurgie und Medizin ( Site 0331), Bern
UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 0332), Zurich
Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 0334), Sankt Gallen
National Taiwan University Hospital-Oncology ( Site 0351), Taipei
Icahn School of Medicine at Mount Sinai ( Site 0009), New York
Seoul National University Bundang Hospital-Medical Oncology ( Site 0290), Seongnam
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0231), Rozzano
Ospedale San Raffaele-Oncologia Medica ( Site 0227), Milan
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013), Baltimore
Blue Ridge Cancer Care ( Site 0008), Roanoke
Charleston Oncology ( Site 0003), Charleston
Hospital Universitario Central de Asturias-Hepatology ( Site 0309), Oviedo
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0230), Napoli
City of Hope Comprehensive Cancer Center ( Site 0002), Duarte
Oregon Health and Science University ( Site 0006), Portland
Virginia Mason Medical Center ( Site 0004), Seattle
Beijing Cancer hospital-Department of Hepato-Pancreato-Biliary Surgery II ( Site 0107), Beijing
Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (, Taipei
Zhongshan Hospital,Fudan University ( Site 0103), Shanghai
Huashan Hospital Affiliated Fudan University-Surgery Department ( Site 0118), Shanghai
Anhui Provincial Hospital ( Site 0113), Hefei
Hunan Cancer Hospital-intervention department ( Site 0109), Changsha
Wuhan Union Hospital Cancer Center ( Site 0108), Wuhan
Southern Medical University Nanfang Hospital-Liver Cancer Department ( Site 0106), Guangzhou
The First Affiliated Hospital of Xian Jiaotong University ward1 depattment of medical oncology ( Sit, Xi'an
National Cancer Center Hospital East ( Site 0153), Kashiwa
Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 0105), Fuzhou
Toranomon Hospital Kajigaya ( Site 0154), Kawasaki
Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site, Sayama
Hiroshima University Hospital ( Site 0156), Hiroshima
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site, Warsaw
Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249), Przemyśl
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0247), Gdansk
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0246), Koszalin
Samsung Medical Center ( Site 0288), Seoul
Asan Medical Center ( Site 0289), Seoul
Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 0310), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY